[Human survivin modified DCs vaccine inhibits laryngeal cancer in vivo and in vitro].
Construction of human full-length survivin gene-modified DCs vaccine and observe the biological characteristics and the role of laryngeal cancer treatment. Construction of homologous recombination through the full-length survivin-human adenovirus (pAd-sur), and transfection of immature DCs, induced by access to sophisticated cultivate DCs, the proliferation of activated T lymphocytes; DCs vaccine different groups observed in vitro, in vivo biological activity. The success in bringing human to build a full-length survivin gene recombinant adenovirus vector pAd-sur; get with the typical characteristics of DCs, the expression level of the surface molecules of up to CD1a 46.2%, CD80 64.2%, CD83 80.5%, HLA-DR 84.3%, vaccine for in vitro cell killing rate 51.5%, compared with the control group, the difference was significant (t = 7.1358, P < 0.01). Gene-modified tumor cell vaccine group was 54.9% of apoptosis and necrosis rate of 21.9%, compared with the control group, the difference was significant (t value was 33.0209 and 17.5057, all P < 0.01). Human full-length survivin gene modified, DCs The expression of surface molecules than the rate of gene-modified DCs without a significant increase, with more to stimulate T lymphocyte proliferation, and promote secretion of gamma-IFN; in vivo, in vitro to promote the ability of anti-laryngeal cancer cells.